BAKER BROS. ADVISORS LP
โขCIK: 1263508โขFiling: Q4 2025
Baker Bros. Advisors LP, helmed by the seasoned duo of John Baker and his son, Mark Baker, manages $17.1 billion with a focus on biotech and healthcare, evident in top holdings like Incyte and OncoCyte. Recently, the fund has made notable moves by adding TECX and PRAX, up 1101% and 809% respectively, while exiting VYLD and NTLA, reflecting a strategy of capitalizing on high-growth potential in emerging biotech sectors.
Total AUM
$17.0B
QoQ Performance
+23.3%
Positions
85
Top 10 Concentration
74.7%
Latest Filing
Q4 2025
Top Holdings Allocation
INCY
ONC
MDGL
IM8N
ACAD
INCY17.8%
ONC15.7%
MDGL7.3%
IM8N6.7%
ACAD6.7%
CELC4.6%
RVMD4.4%
KYMR4.0%
๐ Biggest Buys
๐ Biggest Sells
Sector Breakdown
Other100.0%
๐ช Exited Positionssold since Q3 2025
+8 more exited positions
Changes from Q3 2025
NEW9 new positions
โ23 increased
โ7 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023